OBJECTIVE: We tested the hypothesis that use of and adherence to maintenance medication is low among individuals in the general population who have chronic obstructive pulmonary disease (COPD) , even in cases of severe and very severe COPD. DESIGN AND PARTICIPANTS: We identified 5,812 individuals with COPD from the Copenhagen General Population Study, and classified them according to the Global Initiative for Obstructive Lung Disease (GOLD) airflow limitation grades 1-4. Dispensing of fixed-dose combinations of inhaled corticosteroids with long-acting beta2-agonists, long-acting anti-cholinergics, or long-acting beta2-agonists was identified in a nationwide registry. Use of medication was defined as medication dispensed during a one-year period , and adherence was calculated from dosages available in one year. KEY RESULTS: Use of fixed-dose combinations of inhaled corticosteroids with long-acting beta2-agonists varied from 2 % to 61 % (p < 0.001, test for trend), long-acting anti-cholinergics varied from 0.4 % to 36 % (p < 0.001), and long-acting beta2-agonists varied from 0.3 % to 11 % (p < 0.001. Among utilizers of these medications, adherence varied from 29 % to 56 % (p < 0.001, test for trend) across GOLD 1-4 for fixed-dose combinations of inhaled corticosteroids with long-acting beta2-agonists, from 51 % to 68 % (p = 0.11) for long-acting anti-cholinergics, and from 25 to 62 % (p = 0.01) for long-acting beta2-agonists. CONCLUSIONS: Use of and adherence to maintenance medication for COPD in the general population was associated with the severity of COPD as defined by GOLD, but even in severe and very severe COPD, use and adherence was low.
OBJECTIVE: We tested the hypothesis that use of and adherence to maintenance medication is low among individuals in the general population who have chronic obstructive pulmonary disease (COPD) , even in cases of severe and very severe COPD. DESIGN AND PARTICIPANTS: We identified 5,812 individuals with COPD from the Copenhagen General Population Study, and classified them according to the Global Initiative for Obstructive Lung Disease (GOLD) airflow limitation grades 1-4. Dispensing of fixed-dose combinations of inhaled corticosteroids with long-acting beta2-agonists, long-acting anti-cholinergics, or long-acting beta2-agonists was identified in a nationwide registry. Use of medication was defined as medication dispensed during a one-year period , and adherence was calculated from dosages available in one year. KEY RESULTS: Use of fixed-dose combinations of inhaled corticosteroids with long-acting beta2-agonists varied from 2 % to 61 % (p < 0.001, test for trend), long-acting anti-cholinergics varied from 0.4 % to 36 % (p < 0.001), and long-acting beta2-agonists varied from 0.3 % to 11 % (p < 0.001. Among utilizers of these medications, adherence varied from 29 % to 56 % (p < 0.001, test for trend) across GOLD 1-4 for fixed-dose combinations of inhaled corticosteroids with long-acting beta2-agonists, from 51 % to 68 % (p = 0.11) for long-acting anti-cholinergics, and from 25 to 62 % (p = 0.01) for long-acting beta2-agonists. CONCLUSIONS: Use of and adherence to maintenance medication for COPD in the general population was associated with the severity of COPD as defined by GOLD, but even in severe and very severe COPD, use and adherence was low.
Authors: Truls S Ingebrigtsen; Jacob L Marott; Jørgen Vestbo; Jesper Hallas; Børge G Nordestgaard; Morten Dahl; Peter Lange Journal: Chest Date: 2013-12 Impact factor: 9.410
Authors: Maher R Khdour; Ahmed F Hawwa; Joseph C Kidney; Bronagh M Smyth; James C McElnay Journal: Eur J Clin Pharmacol Date: 2012-04-05 Impact factor: 2.953
Authors: Kylie Hill; Roger S Goldstein; Gordon H Guyatt; Maria Blouin; Wan C Tan; Lori L Davis; Diane M Heels-Ansdell; Marko Erak; Pauline J Bragaglia; Itamar E Tamari; Richard Hodder; Matthew B Stanbrook Journal: CMAJ Date: 2010-04-06 Impact factor: 8.262
Authors: J Vestbo; J A Anderson; P M A Calverley; B Celli; G T Ferguson; C Jenkins; K Knobil; L R Willits; J C Yates; P W Jones Journal: Thorax Date: 2009-08-23 Impact factor: 9.139
Authors: Jennifer S Albrecht; Bilal Khokhar; Ting-Ying Huang; Yu-Jung Wei; Ilene Harris; Patience Moyo; Peter Hur; Susan W Lehmann; Giora Netzer; Linda Simoni-Wastila Journal: Respir Med Date: 2017-06-03 Impact factor: 3.415
Authors: Robert A Wise; Russell A Acevedo; Antonio R Anzueto; Nicola A Hanania; Fernando J Martinez; Jill A Ohar; Donald P Tashkin Journal: Chronic Obstr Pulm Dis Date: 2016-11-15
Authors: Michael Poon; Priscila Pequeno; Shawn D Aaron; Matthew B Stanbrook; Harvey H Wong; Peter Cram; Andrea S Gershon Journal: ERJ Open Res Date: 2022-04-25
Authors: Jennifer S Albrecht; Yujin Park; Peter Hur; Ting-Ying Huang; Ilene Harris; Giora Netzer; Susan W Lehmann; Patricia Langenberg; Bilal Khokhar; Yu-Jung Wei; Patience Moyo; Linda Simoni-Wastila Journal: Ann Am Thorac Soc Date: 2016-09
Authors: Andrea S Gershon; Priscila Pequeno; Amanda Alberga Machado; Shawn D Aaron; Tetyana Kendzerska; Jin Luo; Matthew B Stanbrook; Wan C Tan; Joan Porter; Teresa To Journal: Chest Date: 2021-06-16 Impact factor: 9.410